Physician profile
Prashant Kumar
NPI 1427087071
$11,058.33
in general payments reported to CMS, 2019-2025
37 companies · $1,156 in 2025
The $1,156 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $840 · 2020: $133 · 2021: $79.63 · 2022: $7,052 · 2023: $994 · 2024: $804 · 2025: $1,156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,946 · Education: $7.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,945.98 |
| Education | $7.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $6,688.74 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $783.22 | 2019-2025 | Farxiga, Lokelma, Saphnelo |
| Amgen INC. | $707.40 | 2019-2025 | Evenity, Prolia, Tavneos |
| Ani Pharmaceuticals, INC. | $330.81 | 2024-2025 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $281.44 | 2023-2025 | Jardiance, Ofev |
| Vifor Pharma, INC. | $220.84 | 2019-2025 | Veltassa |
| Janssen Biotech, INC. | $204.90 | 2019-2023 | Tremfya |
| Calliditas Therapeutics US INC. | $197.79 | 2022-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $167.52 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $150.72 | 2023-2025 | Acthar |
| Horizon Therapeutics Plc | $137.31 | 2019-2023 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $131.88 | 2019-2022 | |
| Radius Health, INC. | $126.54 | 2019-2024 | Tymlos |
| Aurinia Pharma U.S., INC. | $115.06 | 2021-2023 | Lupkynis |
| Pfizer INC. | $113.85 | 2023 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $84.45 | 2022-2025 | Jesduvroq, Arexvy, Shingrix |
| Travere Therapeutics, INC. | $68.54 | 2023-2025 | |
| Shield Therapeutics INC | $64.34 | 2024 | |
| Janssen Pharmaceuticals, INC | $54.70 | 2022 | |
| Ardelyx, INC. | $54.17 | 2024-2025 | Ibsrela |
| Mallinckrodt Enterprises LLC | $48.63 | 2019 | |
| Novo Nordisk INC | $47.19 | 2024-2025 | Ozempic, Rybelsus |
| Paratek Pharmaceuticals, INC. | $38.49 | 2023 | Nuzyra |
| Medtronic, INC. | $36.78 | 2022-2023 | Minimed 770g |
| Ucb, INC. | $36.29 | 2023-2024 | Cimzia |
| Merck Sharp & Dohme LLC | $32.74 | 2020-2023 | Verquvo |
| Akebia Therapeutics INC | $27.77 | 2022 | |
| Lilly USA, LLC | $26.37 | 2019-2025 | Jardiance |
| Genentech USA, INC. | $23.10 | 2022 | |
| Philips North America LLC | $16.13 | 2019 | |
| Abbott Laboratories | $15.87 | 2025 | Eterna |
| Cumberland Pharmaceuticals, INC. | $12.79 | 2022 | |
| Nxstage Medical, INC. | $11.96 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prashant Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.